A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50.